Nivalis Therapeutics Inc. (NASDAQ:NVLS) gapped up before the market opened on Monday . The stock had previously closed at $6.33, but opened at $6.40. Nivalis Therapeutics shares last traded at $6.48, with a volume of 25,785 shares.

NVLS has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 8th. Zacks Investment Research downgraded Nivalis Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 2nd. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 1st.

The company’s 50-day moving average price is $5.24 and its 200 day moving average price is $4.69. The company’s market cap is $95.50 million.

Nivalis Therapeutics (NASDAQ:NVLS) last announced its quarterly earnings data on Monday, August 1st. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. On average, equities research analysts expect that Nivalis Therapeutics Inc. will post ($2.29) earnings per share for the current year.

In related news, CMO David Malcom Rodman sold 5,950 shares of the firm’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $4.66, for a total transaction of $27,727.00. Following the completion of the transaction, the chief marketing officer now directly owns 18,055 shares of the company’s stock, valued at $84,136.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.